A patent currently prevents any generic Vyvanse from being manufactured in the United States. The earliest date that a generic version of Vyvanse could be available is in June 2023, when the first patent protecting the medication expires. However, there are other circumstances that could come up to push that date past 2023, such as lawsuits or other patents for specific uses of Vyvanse.
Generic Vyvanse: An OverviewVyvanse™ (lisdexamfetamine dimesylate) is a prescription medication that is approved for treating attention deficit hyperactivity disorder (ADHD) in adults, adolescents, and children age 6 to 12 years old. It belongs to a group of medications known as amphetamines.
Vyvanse is manufactured by Shire US. Vyvanse is currently protected by a patent that prevents any generic Vyvanse from being manufactured in the United States.